Schnitzer

Alliance Resource Partners, L.P. Names Steven Schnitzer Senior Vice President, General Counsel and Secretary

Retrieved on: 
Tuesday, February 27, 2024
Other Energy, Mining, Minerals, Oil, Gas, Coal, Energy, Natural Resources, Acquisition, Senior, EV, Investment, Special counsel, Partnership, Sale, General counsel, Interim, VLTA, Partner, LLP, Schnitzer, DeBevoise, Debevoise & Plimpton, Katten Muchin Rosenman, Corporate group

Alliance Resource Partners, L.P. (NASDAQ: ARLP) today announced that Steven Schnitzer will join ARLP as Senior Vice President, General Counsel and Secretary of Alliance Resource Management GP, LLC, the general partner of ARLP, on March 1, 2024 to lead ARLP's legal activities.

Key Points: 
  • Alliance Resource Partners, L.P. (NASDAQ: ARLP) today announced that Steven Schnitzer will join ARLP as Senior Vice President, General Counsel and Secretary of Alliance Resource Management GP, LLC, the general partner of ARLP, on March 1, 2024 to lead ARLP's legal activities.
  • "Mr. Schnitzer is well-known to ARLP and several members of our management team," said Joseph W. Craft III, Chairman, President and Chief Executive Officer.
  • He is a seasoned general counsel.
  • Mr. Schnitzer will succeed R. Eberley Davis, who will relinquish his legal responsibilities for the Partnership after seventeen years of exemplary service.

MITRE Names New Chief Technology Officer and Corporate Chief Engineer

Retrieved on: 
Monday, October 9, 2023
Research, Other Defense, Contracts, Engineering, Military, Manufacturing, Government Technology, Science, Defense, Virginia Tech, COVID-19, Institute of Electrical and Electronics Engineers, Naval Hospital Boston Historic District, Organization, Massachusetts General Hospital, Shriners, Hospital, Cancer, MITRE, Schnitzer, IR, Harvard Medical School, Electricity, Boston, Security agency, Electronics, Management, Computer security

MITRE ’s Charles Clancy , Ph.D., was named chief technology officer in addition to his role as senior vice president and general manager of MITRE Labs .

Key Points: 
  • MITRE ’s Charles Clancy , Ph.D., was named chief technology officer in addition to his role as senior vice president and general manager of MITRE Labs .
  • Dr. Jay Schnitzer , MITRE’s senior vice president and chief medical officer, was named corporate chief engineer.
  • He will help assure MITRE-wide technical quality and mission impact, support technical staff development, and continue as chief medical officer.
  • Schnitzer joined MITRE in 2013 and has served as the company’s chief technology officer for the past eight years.

Introducing OmniOn Power: Decades of industry-leading power conversion products with a new name

Retrieved on: 
Wednesday, October 4, 2023
5G, Other Energy, Sustainability, Environment, EV, Electric Vehicles, Energy, Automotive, Technology, Omnion, Partnership, Schnitzer, Bell Labs, Telecommunications, ABB, GE, EVS, Renewable energy, Mobile phone

Today, the former ABB Power Conversion division which was recently acquired by AcBel Polytech Inc. unveiled a new identity, OmniOn Power (OmniOn), as part of an extensive rebranding initiative.

Key Points: 
  • Today, the former ABB Power Conversion division which was recently acquired by AcBel Polytech Inc. unveiled a new identity, OmniOn Power (OmniOn), as part of an extensive rebranding initiative.
  • To mark the occasion of its new name, OmniOn has released a State of the Power Conversion Industry report , which explores key insights from market research into the power conversion industry.
  • “Our company has been a leader in the power conversion industry for decades,” said Jeff Schnitzer, president, OmniOn Power.
  • To mark this important moment in the company’s history, OmniOn has issued a State of the Power Conversion Industry report .

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

Retrieved on: 
Monday, October 2, 2023
Alvogen, Priority review, Patent, Partnership, Rockefeller Neuroscience Institute, Schnitzer, Nociception, File, Spinal cord, Clinical trial, Licensure, Coronavirus Scientific Advisory Board, United States patent law, NMDA, Research, CNS, Feinberg School of Medicine, Dark Enlightenment, Data collection, Pain, Thalamus, Investigational New Drug, Patient, Risk, Ketamine, DCS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Northwestern University, Food, Pharmaceutical industry, Poultry farming, Defense, Anesthesia, Chronic pain, IND, Surgery

RADNOR, Pa., Oct. 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.

Key Points: 
  • RADNOR, Pa., Oct. 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.
  • "More than one in five adults in the United States suffers from chronic pain and patients lack options that do not carry the risk of addiction and opioid side effects.
  • Chronic pain is estimated to be a $72 billion industry today with the potential to grow to a $120 billion industry by 2033.
  • Dr. Apkarian is the inventor of the patent and a global expert in pain research and has important experience studying DCS in chronic pain.

Travelers Institute® to Host Travelers Chairman and CEO Alan Schnitzer for Its 100th Wednesdays with Woodward® Webinar

Retrieved on: 
Wednesday, September 27, 2023
Professional Services, Insurance, Business, Thought Leadership, Uncertainty, The Travelers Companies, Schnitzer, Public policy, Traveler, Government, Distracted driving, TRV, NYSE, Management

The Travelers Institute , the public policy division of The Travelers Companies, Inc. (NYSE: TRV ), will celebrate the 100th episode of its Wednesdays with Woodward webinar series Oct. 25 with special guest Alan Schnitzer, Chairman and Chief Executive Officer of Travelers.

Key Points: 
  • The Travelers Institute , the public policy division of The Travelers Companies, Inc. (NYSE: TRV ), will celebrate the 100th episode of its Wednesdays with Woodward webinar series Oct. 25 with special guest Alan Schnitzer, Chairman and Chief Executive Officer of Travelers.
  • Schnitzer will sit down with series creator and host Joan Woodward, President of the Travelers Institute and Executive Vice President of Public Policy at Travelers, for a candid, one-on-one discussion about what leadership looks like in times of uncertainty and rapid change.
  • “Our Wednesdays with Woodward series started as a way to keep us all connected during the pandemic, and it has since grown into one of the most impactful programs in the Travelers Institute’s history,” said Woodward.
  • “It was Alan’s vision 15 years ago that created the Travelers Institute, and we are honored to have him mark our 100th episode.

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

Retrieved on: 
Wednesday, August 30, 2023
Alvogen, Priority review, Patent, Partnership, Rockefeller Neuroscience Institute, Nociception, Schnitzer, Spinal cord, Drug discovery, Clinical trial, Licensure, DSM-IV codes, United States patent law, Coronavirus Scientific Advisory Board, Medication, NMDA, Research, Brain, Tylenol, CNS, Feinberg School of Medicine, Dark Enlightenment, Data collection, Pain, Thalamus, Nonsteroidal anti-inflammatory drug, Ketamine, DCS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Northwestern University, Food, Pharmaceutical industry, Dietary supplement, Vaccine, Poultry farming, Defense, Anesthesia, File, Chronic pain, Surgery

The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.

Key Points: 
  • The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.
  • Chronic pain is estimated to be a $72 billion industry today with the potential to grow to a $120 billion industry by 2033.
  • Dr. Apkarian is the inventor of the patent and a global expert in pain research and has important experience studying DCS in chronic pain.
  • In experimental models and clinical studies, NMDA antagonists have demonstrated attenuation of pain and shown potential to reduce opioid craving.

Schnitzer Reports Third Quarter Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, June 27, 2023
Recycling, Environment, Manufacturing, Steel, Webcast, Calendar, Capital expenditure, 117th United States Congress, Schnitzer, GAAP, SG, Investment, Senior, Bank

Results for the third quarter also included a benefit from average inventory accounting of approximately $2 per ferrous ton, compared to $8 per ferrous ton in the second quarter of fiscal 2023.

Key Points: 
  • Results for the third quarter also included a benefit from average inventory accounting of approximately $2 per ferrous ton, compared to $8 per ferrous ton in the second quarter of fiscal 2023.
  • The effective tax rate for the third quarter of fiscal 2023 was an expense of approximately 34% on GAAP results and approximately 31% on adjusted non-GAAP results.
  • The Board of Directors declared a cash dividend of $0.1875 per common share, payable July 31, 2023 to shareholders of record on July 17, 2023.
  • Schnitzer has paid a dividend every quarter since going public in November 1993.

Schnitzer Steel Named to TIME's List of 100 Most Influential Companies

Retrieved on: 
Wednesday, June 21, 2023
Recycling, Aftermarket, Automotive, Environment, Sustainability, Manufacturing, Steel, Metal, Carbon, Corporate Knights, Ethisphere Institute, Schnitzer Steel, TIME, Fine chemical, Schnitzer

Today, Schnitzer Steel Industries, Inc. (NASDAQ: SCHN), a global leader in metals recycling, was named to TIME’s third-annual TIME100 Most Influential Companies list.

Key Points: 
  • Today, Schnitzer Steel Industries, Inc. (NASDAQ: SCHN), a global leader in metals recycling, was named to TIME’s third-annual TIME100 Most Influential Companies list.
  • The ranking highlights 100 companies that are making an extraordinary impact around the world.
  • “We are honored to be a part of TIME’s list of the 100 Most Influential Companies,” said Tamara Lundgren, Chairman and CEO of Schnitzer.
  • The full list of TIME’s Most Influential Companies of 2023: time.com/100companies

Schnitzer Named One of the 2023 World’s Most Ethical Companies

Retrieved on: 
Monday, March 13, 2023
Machine Tools, Metalworking & Metallurgy, Recycling, Environment, Manufacturing, Other Manufacturing, Machinery, Steel, Organization, Core values, Integrity, Chief ethics officer, Ethisphere Institute, Metal, Ethics, Culture, Schnitzer, Safety

Schnitzer Steel Industries, Inc. (NASDAQ: SCHN), a global leader in metals recycling, has been recognized by Ethisphere as one of the 2023 World’s Most Ethical Companies .

Key Points: 
  • Schnitzer Steel Industries, Inc. (NASDAQ: SCHN), a global leader in metals recycling, has been recognized by Ethisphere as one of the 2023 World’s Most Ethical Companies .
  • “We are honored to be recognized as one of the World’s Most Ethical Companies for the ninth consecutive year,” said Tamara Lundgren, Chairman and Chief Executive Officer.
  • “Being included on Ethisphere’s prestigious list of the World’s Most Ethical Companies is one of the highest and most valuable honors our Company can receive.
  • “We are immensely proud to be recognized again as one of the World’s Most Ethical Companies, alongside a global community of companies dedicated to raising the bar on ethical leadership and social responsibility.”
    “Ethics matters.

FCW Selects MITRE’s Dr. Jay Schnitzer as a 2023 Federal 100 Honoree

Retrieved on: 
Monday, February 27, 2023
Data Management, Other Science, Practice Management, Technology, Research, General Health, Public Policy, Government, Other Health, Surgery, Pharmaceutical, Oncology, Health Technology, Hospitals, Clinical Trials, Cardiology, Biotechnology, Software, Health, White House, Federal Government, Science, Cancer, Joe Biden, Partnership, National Cancer Institute, Health information management, HL7, Patient, Health Level Seven International, Doctor of Philosophy, Schnitzer, Electronic health record, White, FCW, Stanford Law School, MITRE, Language, Nursing, Medical imaging, MD

FCW named Jay Schnitzer , MD, Ph.D., MITRE chief technology and medical officer, to the 2023 Federal 100 for his leadership in enabling better health outcomes for patients by unlocking the vast research and treatment insights of interoperable electronic health records (EHRs).

Key Points: 
  • FCW named Jay Schnitzer , MD, Ph.D., MITRE chief technology and medical officer, to the 2023 Federal 100 for his leadership in enabling better health outcomes for patients by unlocking the vast research and treatment insights of interoperable electronic health records (EHRs).
  • Schnitzer guides MITRE’s $100M independent research and development portfolio , including the company’s initiative to use patient data to help cure cancer.
  • FCW will honor the Federal 100 award winners at a ceremony in Washington, D.C., on April 20.
  • For 34 years, the awards have celebrated government, industry, and academic leaders who are transforming government and its ability to deliver on critical missions.